Developer docs
API playgroundTry for free, no card

Search company profiles

NETRI

Full company profile

uuid00021sy

Namestring
NETRI
Legal namestring
NETRI
Websiteurl
netri.fr
Company typeenum
Private
Founded yearint
2018
Descriptiontext

NETRI is a French industrial start-up founded in 2018 and headquartered in Lyon, France, that develops microphysiological systems (MPS) and organ-on-chip technologies for the pharmaceutical, biotech, cosmetics, and academic research markets. Its core offering is a standardized compartmentalized electrophysiology platform described as the world's only 96-well format system of its kind, in which living neurons are used as biological sensors — the company's "Neurons-as-a-Sensor" (NaaS) approach — to predict drug-induced neurotoxicity, chemotherapy adverse events, immune responses, and dermatological/cosmetic effects such as itching or irritation. The platform is paired with two proprietary software components, NETRI UpLink® (which extracts Multi-Electrode Array metrics from recordings) and DataLink® (which compiles n-dimensional digital signatures from those metrics), and is benchmarked against a proprietary Digital Signature Library of reference compounds.

NETRI operates a hybrid B2B business model. Commercial revenue is generated through direct enterprise sales of custom organ-on-chip configurations to pharmaceutical, biotech, dermocosmetics, and academic customers, complemented by a self-service e-commerce storefront (shop.netri.com) selling standardized organs-on-chip kits. The company also monetizes consumable wetware/reagents on a usage basis and licenses its software stack, creating a mix of hardware, recurring software, and consumable revenue streams. The company is privately held, employs 11–50 people, and is co-led by CEO Thibault Honegger and CTO/co-founder Florian Larramendy. In February 2025 NETRI raised approximately $5.1 million in funding, and in 2026 it co-founded the Industry Alliance for Microphysiological Systems (IAMPS), the first industry association of its kind in Europe, alongside eight peer MPS providers.

Short descriptiontext

NETRI is a French organ-on-chip company that uses neurons as biological sensors in the world's only 96-well format compartmentalized electrophysiology platform to predict drug safety, neurotoxicity, and sensory effects for pharma, biotech, cosmetics, and academic research customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
organ-on-chip technology, microphysiological systems, preclinical drug testing, electrophysiology platforms, neurotoxicity screening
Industry2 codes
PRIMARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAB
Safety Pharmacology (Cardio/CNS/Respiratory)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Surgical & Medical Instruments & Apparatus3841
Product category
Organ-on-Chip Technology
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Organ-on-Chip Hardware and Kits
TypeHardware Sales
Description

Sale of organs-on-chip devices and standardized microphysiological system kits including neuro-organs-on-chip devices for research applications.

netri.com
2Software Platforms
TypeSubscription Recurring
Description

Licensing and sale of proprietary software platforms including NETRI UpLink® and DataLink® for electrophysiological data capture and analysis.

netri.com
3Wetware/Reagents
TypeUsage Based
Description

Consumable biological materials and reagents for microphysiological system experiments.

netri.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NETRI develops and sells standardized microphysiological systems (organ-on-chip platforms) and proprietary software for preclinical drug safety and efficacy testing. The offering includes the world's only 96-well format compartmentalized electrophysiology platform, organs-on-chip kits, the NETRI UpLink® and DataLink® software platforms for Multi-Electrode Array (MEA) data analysis, and a Digital Signature Library of reference compounds. The technology applies a Neurons-as-a-Sensor (NaaS) approach, using living neurons as biological sensors to predict drug-induced effects including neurotoxicity, chemotherapy adverse events, and dermatological/sensory responses for pharmaceutical, biotech, cosmetics, and academic customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 87% sensitivity in predicting drug-induced liver injury
+1 more record
Product overview1 text field

NETRI offers a unified platform of standardized microphysiological systems and neurons-as-a-sensor (NaaS) technology for preclinical drug testing. The core offering centers on compartmentalized electrophysiology platforms—the world's only 96-well format system—which integrate with proprietary software components NETRI UpLink® (for extracting MEA metrics) and DataLink® (for compiling digital signatures). Results are analyzed against a Digital Signature Library of reference compounds. The product portfolio spans organs-on-chip kits for quick adoption, specialized applications in dermocosmetics, neurotoxicology, oncology, and dermatology testing, and technology components (hardware, wetware, software) available through dedicated pages.

Product and service5 records
1Standardized Microphysiological Systems (Compartmentalized Electrophysiology Platforms)
2Organs-on-Chip Kits
3Neurons as a Sensor (NaaS)
4NETRI UpLink®
5DataLink®
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-10
Description

NETRI is a founding member of IAMPS, the world's first industry association dedicated to representing microphysiological systems providers across Europe. The association, operational from Q2 2026, aims to increase regulatory acceptance of MPS data, create data-sharing platforms, and advance device standardization. Founding members include nine companies: Alveolix, BiomimX, Chiron, Dynamic42, InSphero, MIMETAS, NETRI, React4Life, and TissUse, headquartered in Switzerland, Italy, the Netherlands, Germany, and France.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-10
Description

Swiss-based founding member of IAMPS (Industry Alliance for Microphysiological Systems), collaborating with NETRI on advancing microphysiological systems industry standards and regulatory acceptance.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-10
Description

Netherlands-based founding member of IAMPS, collaborating with NETRI on microphysiological systems standardization and regulatory data acceptance initiatives.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-10
Description

German-based founding member of IAMPS, partnering with NETRI on advancing organ-on-chip technology standards and industry collaboration.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-10
Description

German-based founding member of IAMPS, collaborating with NETRI on microphysiological systems data sharing and device standardization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-10
Description

Italian-based founding member of IAMPS, partnering with NETRI on MPS industry advancement and regulatory acceptance.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-10
Description

Founding member of IAMPS, collaborating with NETRI on microphysiological systems industry association initiatives.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-10
Description

German-based founding member of IAMPS, partnering with NETRI on microphysiological systems standardization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-10
Description

Italian-based founding member of IAMPS, collaborating with NETRI on advancing microphysiological systems technology and regulatory frameworks.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

MIMETAS is a Netherlands-based organ-on-chip company offering the OrganoPlate platform for high-throughput 3D cell-based assays. It is a direct competitor to NETRI in organ-on-chip hardware and reagents, and is a co-founding member of IAMPS alongside NETRI.

TypeDirect peer
Description

TissUse is a German organ-on-chip company developing multi-organ microphysiological systems (Humimic Chip series) for preclinical safety and efficacy testing. It competes directly with NETRI's microphysiological systems and is a co-founding member of IAMPS.

TypeDirect peer
Description

Emulate is a US-based leader in organ-on-chip technology, commercializing the Organ-Chip platform and supporting software for pharma R&D. It competes with NETRI in the same product category and target customer base, with broader organ coverage and greater commercial scale.

TypeDirect peer
Description

InSphero is a Swiss/German company specializing in 3D microtissue and organ-on-chip solutions for drug safety and efficacy testing. It competes directly with NETRI for pharma toxicology budgets and is a co-founding member of IAMPS.

5CN Bio
TypeDirect peer
Description

CN Bio is a UK-based organ-on-chip company offering PhysioMimix single- and multi-organ microphysiological systems for ADME and toxicology applications. It is a direct competitor targeting the same pharma safety-testing use cases as NETRI.

TypeDirect peer
Description

Alveolix is a Swiss organ-on-chip company focused on lung-on-chip applications for respiratory drug testing. It is a co-founding IAMPS member alongside NETRI and competes in the broader microphysiological systems category.

TypeDirect peer
Description

BiomimX is an Italian organ-on-chip company developing multi-organ microphysiological platforms for drug discovery. It is a co-founding IAMPS member with NETRI and competes in the same European MPS ecosystem.

TypeDirect peer
Description

Dynamic42 is a German organ-on-chip company providing human organ models (liver, gut, lung) for preclinical drug testing and infectious disease research. It is a co-founding IAMPS member alongside NETRI.

TypeDirect peer
Description

React4Life is an Italian company developing microfluidic 3D cell-culture and organ-on-chip platforms for pharma and cosmetics applications. It is a co-founding IAMPS member with NETRI, overlapping in cosmetics and preclinical safety use cases.

TypeBroad incumbent
Description

Cyprotex, owned by Evotec, is a leading CRO providing in vitro ADME and toxicology services including organ-on-chip-based assays. It is comparable to NETRI as a buyer-facing preclinical safety service provider, though operating as a broad incumbent with a much wider service portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NETRI

Organ-on-Chip Technologynetri.fr

NETRI is a French organ-on-chip company that uses neurons as biological sensors in the world's only 96-well format compartmentalized electrophysiology platform to predict drug safety, neurotoxicity, and sensory effects for pharma, biotech, cosmetics, and academic research customers.

What NETRI does

NETRI is a French industrial start-up founded in 2018 and headquartered in Lyon, France, that develops microphysiological systems (MPS) and organ-on-chip technologies for the pharmaceutical, biotech, cosmetics, and academic research markets. Its core offering is a standardized compartmentalized electrophysiology platform described as the world's only 96-well format system of its kind, in which living neurons are used as biological sensors — the company's "Neurons-as-a-Sensor" (NaaS) approach — to predict drug-induced neurotoxicity, chemotherapy adverse events, immune responses, and dermatological/cosmetic effects such as itching or irritation. The platform is paired with two proprietary software components, NETRI UpLink® (which extracts Multi-Electrode Array metrics from recordings) and DataLink® (which compiles n-dimensional digital signatures from those metrics), and is benchmarked against a proprietary Digital Signature Library of reference compounds.

NETRI operates a hybrid B2B business model. Commercial revenue is generated through direct enterprise sales of custom organ-on-chip configurations to pharmaceutical, biotech, dermocosmetics, and academic customers, complemented by a self-service e-commerce storefront (shop.netri.com) selling standardized organs-on-chip kits. The company also monetizes consumable wetware/reagents on a usage basis and licenses its software stack, creating a mix of hardware, recurring software, and consumable revenue streams. The company is privately held, employs 11–50 people, and is co-led by CEO Thibault Honegger and CTO/co-founder Florian Larramendy. In February 2025 NETRI raised approximately $5.1 million in funding, and in 2026 it co-founded the Industry Alliance for Microphysiological Systems (IAMPS), the first industry association of its kind in Europe, alongside eight peer MPS providers.

NETRI firmographics

Firmographics
Name
NETRI
Legal name
NETRI
Website
https://netri.fr
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
NETRI is a French organ-on-chip company that uses neurons as biological sensors in the world's only 96-well format compartmentalized electrophysiology platform to predict drug safety, neurotoxicity, and sensory effects for pharma, biotech, cosmetics, and academic research customers.
Ownership category
akta.pro rank

NETRI industry classification

Industry
Product category
Organ-on-Chip Technology
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAB
Safety Pharmacology (Cardio/CNS/Respiratory)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • Organ-on-chip technology
  • Microphysiological systems
  • Preclinical drug testing
  • Electrophysiology platforms
  • Neurotoxicity screening

Where NETRI is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Offices1 record

Markets served

NETRI business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Organ-on-Chip Hardware and Kits: Sale of organs-on-chip devices and standardized microphysiological system kits including neuro-organs-on-chip devices for research applications.
  2. Software Platforms: Licensing and sale of proprietary software platforms including NETRI UpLink® and DataLink® for electrophysiological data capture and analysis.
  3. Wetware/Reagents: Consumable biological materials and reagents for microphysiological system experiments.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

NETRI product offering

Product offering

Core offering

NETRI develops and sells standardized microphysiological systems (organ-on-chip platforms) and proprietary software for preclinical drug safety and efficacy testing. The offering includes the world's only 96-well format compartmentalized electrophysiology platform, organs-on-chip kits, the NETRI UpLink® and DataLink® software platforms for Multi-Electrode Array (MEA) data analysis, and a Digital Signature Library of reference compounds. The technology applies a Neurons-as-a-Sensor (NaaS) approach, using living neurons as biological sensors to predict drug-induced effects including neurotoxicity, chemotherapy adverse events, and dermatological/sensory responses for pharmaceutical, biotech, cosmetics, and academic customers.

Product overview

NETRI offers a unified platform of standardized microphysiological systems and neurons-as-a-sensor (NaaS) technology for preclinical drug testing. The core offering centers on compartmentalized electrophysiology platforms—the world's only 96-well format system—which integrate with proprietary software components NETRI UpLink® (for extracting MEA metrics) and DataLink® (for compiling digital signatures). Results are analyzed against a Digital Signature Library of reference compounds. The product portfolio spans organs-on-chip kits for quick adoption, specialized applications in dermocosmetics, neurotoxicology, oncology, and dermatology testing, and technology components (hardware, wetware, software) available through dedicated pages.

Differentiator

Problem solved

Functional benefit

Products and services

  • Standardized Microphysiological Systems (Compartmentalized Electrophysiology Platforms)
  • Organs-on-Chip Kits
  • Neurons as a Sensor (NaaS)
  • NETRI UpLink®
  • DataLink®

Quantifiable outcome

  • 87% sensitivity in predicting drug-induced liver injury
  • +1 more outcomes

Companies that use NETRI

Customer profile

Segments4 records

Ideal customer profiles4 records

NETRI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

NETRI partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core.

  • IAMPS (Industry Alliance for Microphysiological Systems)coreStrategic or Co-development Partner · 10 February 2026NETRI is a founding member of IAMPS, the world's first industry association dedicated to representing microphysiological systems providers across Europe. The association, operational from Q2 2026, aims to increase regulatory acceptance of MPS data, create data-sharing platforms, and advance device standardization. Founding members include nine companies: Alveolix, BiomimX, Chiron, Dynamic42, InSphero, MIMETAS, NETRI, React4Life, and TissUse, headquartered in Switzerland, Italy, the Netherlands, Germany, and France.
  • AlveolixcoreStrategic or Co-development Partner · 10 February 2026Swiss-based founding member of IAMPS (Industry Alliance for Microphysiological Systems), collaborating with NETRI on advancing microphysiological systems industry standards and regulatory acceptance.
  • MIMETAScoreStrategic or Co-development Partner · 10 February 2026Netherlands-based founding member of IAMPS, collaborating with NETRI on microphysiological systems standardization and regulatory data acceptance initiatives.
  • InSpherocoreStrategic or Co-development Partner · 10 February 2026German-based founding member of IAMPS, partnering with NETRI on advancing organ-on-chip technology standards and industry collaboration.
  • TissUsecoreStrategic or Co-development Partner · 10 February 2026German-based founding member of IAMPS, collaborating with NETRI on microphysiological systems data sharing and device standardization.
  • BiomimXcoreStrategic or Co-development Partner · 10 February 2026Italian-based founding member of IAMPS, partnering with NETRI on MPS industry advancement and regulatory acceptance.
  • ChironcoreStrategic or Co-development Partner · 10 February 2026Founding member of IAMPS, collaborating with NETRI on microphysiological systems industry association initiatives.
  • Dynamic42coreStrategic or Co-development Partner · 10 February 2026German-based founding member of IAMPS, partnering with NETRI on microphysiological systems standardization.
  • React4LifecoreStrategic or Co-development Partner · 10 February 2026Italian-based founding member of IAMPS, collaborating with NETRI on advancing microphysiological systems technology and regulatory frameworks.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

NETRI competitors and assessment

Company assessment

Direct peers

  • MIMETAS: MIMETAS is a Netherlands-based organ-on-chip company offering the OrganoPlate platform for high-throughput 3D cell-based assays. It is a direct competitor to NETRI in organ-on-chip hardware and reagents, and is a co-founding member of IAMPS alongside NETRI.
  • TissUse: TissUse is a German organ-on-chip company developing multi-organ microphysiological systems (Humimic Chip series) for preclinical safety and efficacy testing. It competes directly with NETRI's microphysiological systems and is a co-founding member of IAMPS.
  • Emulate: Emulate is a US-based leader in organ-on-chip technology, commercializing the Organ-Chip platform and supporting software for pharma R&D. It competes with NETRI in the same product category and target customer base, with broader organ coverage and greater commercial scale.
  • InSphero: InSphero is a Swiss/German company specializing in 3D microtissue and organ-on-chip solutions for drug safety and efficacy testing. It competes directly with NETRI for pharma toxicology budgets and is a co-founding member of IAMPS.
  • CN Bio: CN Bio is a UK-based organ-on-chip company offering PhysioMimix single- and multi-organ microphysiological systems for ADME and toxicology applications. It is a direct competitor targeting the same pharma safety-testing use cases as NETRI.
  • Alveolix: Alveolix is a Swiss organ-on-chip company focused on lung-on-chip applications for respiratory drug testing. It is a co-founding IAMPS member alongside NETRI and competes in the broader microphysiological systems category.
  • BiomimX: BiomimX is an Italian organ-on-chip company developing multi-organ microphysiological platforms for drug discovery. It is a co-founding IAMPS member with NETRI and competes in the same European MPS ecosystem.
  • Dynamic42: Dynamic42 is a German organ-on-chip company providing human organ models (liver, gut, lung) for preclinical drug testing and infectious disease research. It is a co-founding IAMPS member alongside NETRI.
  • React4Life: React4Life is an Italian company developing microfluidic 3D cell-culture and organ-on-chip platforms for pharma and cosmetics applications. It is a co-founding IAMPS member with NETRI, overlapping in cosmetics and preclinical safety use cases.

Broad incumbents

  • Cyprotex (an Evotec company): Cyprotex, owned by Evotec, is a leading CRO providing in vitro ADME and toxicology services including organ-on-chip-based assays. It is comparable to NETRI as a buyer-facing preclinical safety service provider, though operating as a broad incumbent with a much wider service portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

NETRI social profiles

Digital presence

NETRI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NETRI leadership team

Management profile

Number of profiles

Profiles2 records

NETRI funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NETRI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NETRI

What does NETRI do?

NETRI develops and sells standardized microphysiological systems (organ-on-chip platforms) and proprietary software for preclinical drug safety and efficacy testing. The offering includes the world's only 96-well format compartmentalized electrophysiology platform, organs-on-chip kits, the NETRI UpLink® and DataLink® software platforms for Multi-Electrode Array (MEA) data analysis, and a Digital Signature Library of reference compounds. The technology applies a Neurons-as-a-Sensor (NaaS) approach, using living neurons as biological sensors to predict drug-induced effects including neurotoxicity, chemotherapy adverse events, and dermatological/sensory responses for pharmaceutical, biotech, cosmetics, and academic customers.

Is NETRI a public or private company?

NETRI is a private company. It is classified as unknown and is currently operating.

When was NETRI founded?

NETRI was founded in 2018. It employs 11 to 50 people.

Where is NETRI based?

NETRI is headquartered in Lyon, France, in the Europe region.

How does NETRI make money?

Three revenue lines are on record. Organ-on-Chip Hardware and Kits are the primary driver. The others are software Platforms and wetware/Reagents.

Who are NETRI's main competitors?

Direct peers on record are MIMETAS, TissUse, Emulate, InSphero, CN Bio, Alveolix, BiomimX, Dynamic42 and React4Life. Cyprotex (an Evotec company) is listed as a broad incumbent.

Does NETRI have an API?

No public API is recorded for NETRI.

What industry is NETRI in?

NETRI's product category is Organ-on-Chip Technology. Its primary akta.pro industry code is HLAGAFAJ, In Vitro Toxicology (Cell-based/Organ-on-chip), with a secondary code of HLAGAFAB, Safety Pharmacology (Cardio/CNS/Respiratory). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals